PL1988913T3 - Ciekły preparat G-CSF - Google Patents

Ciekły preparat G-CSF

Info

Publication number
PL1988913T3
PL1988913T3 PL07712399T PL07712399T PL1988913T3 PL 1988913 T3 PL1988913 T3 PL 1988913T3 PL 07712399 T PL07712399 T PL 07712399T PL 07712399 T PL07712399 T PL 07712399T PL 1988913 T3 PL1988913 T3 PL 1988913T3
Authority
PL
Poland
Prior art keywords
csf
polysorbate
liquid formulation
pharmaceutical adjuvants
acetate
Prior art date
Application number
PL07712399T
Other languages
English (en)
Inventor
Michael Mack
Ulrich Kurt Blaschke
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38226349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1988913(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Publication of PL1988913T3 publication Critical patent/PL1988913T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07712399T 2006-03-01 2007-03-01 Ciekły preparat G-CSF PL1988913T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006009437A DE102006009437A1 (de) 2006-03-01 2006-03-01 G-CSF-Flüssigformulierung
PCT/EP2007/051947 WO2007099145A1 (de) 2006-03-01 2007-03-01 G-csf-flüssigformulierung
EP07712399A EP1988913B1 (de) 2006-03-01 2007-03-01 G-csf-flüssigformulierung

Publications (1)

Publication Number Publication Date
PL1988913T3 true PL1988913T3 (pl) 2009-09-30

Family

ID=38226349

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07712399T PL1988913T3 (pl) 2006-03-01 2007-03-01 Ciekły preparat G-CSF

Country Status (14)

Country Link
US (1) US20090247450A1 (pl)
EP (2) EP1988913B1 (pl)
JP (1) JP2009528327A (pl)
AT (1) ATE429243T1 (pl)
CA (1) CA2644461A1 (pl)
CY (1) CY1109223T1 (pl)
DE (4) DE202006020194U1 (pl)
DK (1) DK1988913T3 (pl)
ES (1) ES2326498T3 (pl)
PL (1) PL1988913T3 (pl)
PT (1) PT1988913E (pl)
RU (1) RU2445115C2 (pl)
SI (1) SI1988913T1 (pl)
WO (1) WO2007099145A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2006010143A2 (en) * 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
DK2197919T3 (da) * 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
PT2076243E (pt) * 2007-08-27 2014-12-05 Ratiopharm Gmbh Formulação líquida de g-csf
DE202007018629U1 (de) * 2007-08-27 2008-12-24 Biogenerix Ag Flüssigformulierung von G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3537708A1 (de) 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FI900178A0 (fi) 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
DE3835350A1 (de) 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
FR2669646A1 (fr) 1990-11-23 1992-05-29 Lorraine Laminage Procede de traitement d'un effluent aqueux issu d'un procede d'electrozingage, ainsi que procede et installation en comportant application.
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
GB9300356D0 (en) * 1993-01-09 1993-03-03 Tbs Eng Ltd Apparatus for assembling battery plates
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
ATE260674T1 (de) 1998-08-17 2004-03-15 Pfizer Prod Inc Stabilisierte proteinzusammensetzung
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
CN1878570B (zh) 2003-11-04 2010-10-06 力奇制药公司 包含粒细胞集落形成刺激因子的稳定的药物组合物
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung

Also Published As

Publication number Publication date
CA2644461A1 (en) 2007-09-07
DK1988913T3 (da) 2009-08-17
RU2008138646A (ru) 2010-04-10
WO2007099145A1 (de) 2007-09-07
DE502007000649D1 (de) 2009-06-04
DE202007018618U1 (de) 2008-12-11
ATE429243T1 (de) 2009-05-15
RU2445115C2 (ru) 2012-03-20
CY1109223T1 (el) 2014-07-02
ES2326498T3 (es) 2009-10-13
US20090247450A1 (en) 2009-10-01
EP1988913B1 (de) 2009-04-22
DE102006009437A1 (de) 2007-09-13
SI1988913T1 (sl) 2009-10-31
JP2009528327A (ja) 2009-08-06
EP1988913A1 (de) 2008-11-12
EP2098243A1 (de) 2009-09-09
PT1988913E (pt) 2009-07-16
DE202006020194U1 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
SI1988913T1 (sl) Tekoča formulacija G-CSF
TW200716202A (en) Pediatric formulation of topiramate
WO2007081579A3 (en) Foam/spray producing compositions and dispensing system therefor
TW200640908A (en) Chemical compounds
WO2005037246A3 (de) Wässrige aerosol-zubereitung
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2009033785A3 (en) Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
AR058586A1 (es) Compuesto de 2-carboxitiofeno, formulacion farmaceutica que lo comprende, su uso para la preparacion de un medicamento y combinacion de dicho compuesto con otro agente terapeuticamente activo
EP1803469A3 (en) Medicaments for inhalation comprising betamimetics and an anticholinergic
WO2006040112A3 (en) Taste-masking pharmaceutical compositions
WO2007071965A3 (en) Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
IL182135A0 (en) Liquid allergy vaccine formulation for ormucosal administration
MY148124A (en) Preparation of a crystalline antibiotic substance
WO2007121471A3 (en) Dialkyl ether delivery agents
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
WO2004066863A3 (en) Immunopotentiating agent for use in animals
PL1970372T3 (pl) Sole kwasu 9-oksoakrydyno-10-octowego z 1-alkiloamino-1-deoksypoliolami